iPROLEPSIS - a HorizonEurope-funded project that aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale/multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioral) data, digital phenotyping of inflammatory symptoms with emphasis on tracking of motor manifestations using smart devices and wearables, novel optoacoustic imaging-based markers of PsA in the skin and joints, and investigation of the role of mast cells in the PsA transition, to identify key drivers of the disease and support personalized models for PsA risk/progression prediction and monitoring as well as associated inflammation detection and severity assessment.
iPROLEPSIS receives funding from Horizon Europe under Grant Agreement No 101095697.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority. Neither the European Union nor the granting authority can be held responsible for them.
Company Details
- Founded
- -
- Address
- Thessaloniki , Gr
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- http://www.iprolepsis.eu
- HQ
- Thessaloniki
Iprolepsis Questions
Iprolepsis's website is http://www.iprolepsis.eu
Iprolepsis's LinkedIn profile is https://gr.linkedin.com/company/iprolepsis
Iprolepsis's industry is
Research Services
Iprolepsis's top competitors are
Relevium Project,
Ai-Prognosis,
Igem Thessaloniki,
Stratifyhf Eu Project,
Smartchange,
Ainigma Technologies,
Biomed - Ku Leuven,
Dioptra Project,
Hippocrates Imi,
Signal Processing & Biomedical Technology Unit - Auth.
Iprolepsis's categories are Research Services
Iprolepsis's founding year is 2023
